GFM
VOR icon

GF Fund Management’s Vor Biopharma VOR Stock Holding History

GF Fund Management’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.64K Buy
372
+42
+13% +$592 ﹤0.01% 591
2025
Q4 		$4.32K Buy
+330
New +$6.14K ﹤0.01% 626

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GF Fund Management's VOR Position: Q1 2026 in Review

GF Fund Management increased its Vor Biopharma (VOR) stake by 13% in Q1 2026, buying an estimated $592 and bringing the position to 372 shares worth $6.64K. The position accounts for ﹤0.01% of the portfolio, ranked #591.

GF Fund Management first reported a position in VOR in Q4 2025 and has held it in 2 quarters since. 80 funds tracked by Wall St. Rank hold VOR as of Q1 2026.

  • GF Fund Management held 372 shares of Vor Biopharma worth $6.64K as of Q1 2026.
  • GF Fund Management bought 42 Vor Biopharma shares in Q1 2026, an estimated $592.
  • Vor Biopharma made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #591 holding.
  • GF Fund Management first reported a position in Vor Biopharma in Q4 2025 and has held it in 2 quarters since.
  • 80 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.